TG Therapeutics, Inc.
TGTX$2.50B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK374 employees
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Sep 1, 2026
22wMarket Overview
Stock performance and key metrics
TGTX News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
Teriflunomide
Relapsing Multiple Sclerosis (RMS)
Ublituximab
Non-Hodgkins Lymphoma
Ibrutinib
Chronic Lymphocytic Leukemia
Umbralisib
Marginal Zone Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis (RMS) | - | - |
Ublituximab | Phase 3 | Non-Hodgkins Lymphoma | - | - |
Ibrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Umbralisib | Phase 2 | Marginal Zone Lymphoma | - | - |
Relapsing Multiple Sclerosis (RMS)
2 drugs in this indication
Marginal Zone Lymphoma
1 drug in this indication
Non-Hodgkins Lymphoma
1 drug in this indication
Chronic Lymphocytic Leukemia
1 drug in this indication
Relapsing Multiple Sclerosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply